List view / Grid view
24 March 2015 | By Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
23 March 2015 | By Victoria White
Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...
20 March 2015 | By Victoria White
ExpreS2ion Biotechnologies announce the release by its partners at University of Copenhagen of a vaccine against placental malaria for testing in humans...
19 March 2015 | By Victoria White
MISSION Therapeutics announces the appointment of Paul Wallace PhD as Chief Business Officer...
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
9 March 2015 | By Edinburgh Research and Innovation
University of Edinburgh spin-out company Parkure Ltd has successfully attracted over £75,000 in crowdfunding investment through ShareIn, the technology-focussed crowdfunding firm, to develop a cure for Parkinson’s disease...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
25 February 2015 | By Oxford Global
Oxford Global are proud to present its 3rd Annual Discovery Chemistry & Drug Design will be on the 8th and 9th of June 2015...
25 February 2015 | By Oxford Global
Oxford Global are proud to present its 16th Annual Drug Discovery Congress will be on the 8th and 9th of June 2015...
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
9 February 2015 | By SensiQ Technologies/Inventiva
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation...
4 February 2015 | By Frost & Sullivan
Ongoing research aims to develop oncologic imaging technologies that diagnose cancer at the cellular level before the disease manifests, finds Frost & Sullivan...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
DNA sequencing technologies have come on leaps and bounds since the double-helical structure of DNA was first discovered in 1953 by genetics pioneers James Watson and Francis Crick. This discovery paved the way to the development, years later, of next generation sequencing (NGS), a high-throughput technology that enables scientists to…
